SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  For example, here is how to disable FireFox ad content blocking while on Silicon Investor.
Biotech / Medical : Immunomedics (IMMU) - moderated
IMMU 16.59-2.7%Sep 20 4:00 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Fitzhughlaw who wrote (52460)9/11/2019 9:29:08 PM
From: weatherproof13 Recommendations

Recommended By
allatwwk
bnutman
bobbseytwins2001
captcobra1
chandler27

and 8 more members

   of 52512
 
As to IMMU-132 vs. EV:

1. As Idaho indicated, as long as SGEN hasn't moved past AA and received full approval on their ph IV confirmatory trial, IMMU-132 is still eligible for AA, and then full approval of 132.

2. In the case of DS, the approach involves a similar mechanism of action as that of IMMU-132, targeting the same target, TROP-2, This is not the case with EV, so there is room for both EV and 132, which is further supported by the notion that there appears to be no overlapping toxicities with those therapeutic approaches.

3. Most patients dealing with bladder cancer are older and drug safety is going to be important in terms of keeping these patients on the drug. It appears IMMU's safety profile is favorable as compared to EV. This safety advantage is significant in terms of the biologic's use in early lines of treatment and in combination applications.

4. The exclusion for neuropathies for EV is particularly noteworthy as that is a lingering side effect for platinum-based therapies which will precede use of SGEN's EV for platinum-eligible patients.

On another note, we not only see the toxicity associated with Daiichi Sankyo's DS-1062, but we see suspension of Pfizer's TROP-2 ADC, as mentioned by Behzad in his recent fireside chat. This reinforces the importance of discovering the right balance of antibody, linker and drug conjugate which has escaped many companies with much larger R&D budgets.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext